Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Operations (Unaudited)

v3.5.0.2
Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
NET REVENUE        
Clinical testing revenue $ 56,316 $ 24,055 $ 110,936 $ 46,894
BioPharma & research revenue 6,813 315 11,896 502
Total Revenue, net 63,129 24,370 122,832 47,396
COST OF REVENUE 34,524 13,557 67,055 27,040
GROSS MARGIN 28,605 10,813 55,777 20,356
Operating expenses:        
General and administrative 18,779 7,075 36,785 13,598
Research and development 1,306 803 2,752 1,471
Sales and marketing 6,327 2,907 12,127 5,821
Total Operating Expenses 26,412 10,785 51,664 20,890
INCOME (LOSS) FROM OPERATIONS 2,193 28 4,113 (534)
Interest expense, net 1,448 189 3,040 384
Income (loss) before taxes 745 (161) 1,073 (918)
Income tax expense 332 15 505 19
NET INCOME (LOSS) 413 (176) 568 (937)
Deemed dividends on preferred stock 1,840   3,680  
Amortization of preferred stock beneficial conversion feature 3,727   7,453  
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS $ (5,154) $ (176) $ (10,565) $ (937)
NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS        
Basic $ (0.07) $ 0.00 $ (0.14) $ (0.02)
Diluted $ (0.07) $ 0.00 $ (0.14) $ (0.02)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:        
Basic 77,448 60,425 76,758 60,352
Diluted 77,448 60,425 76,758 60,352